Literature DB >> 17126282

Characterization of an alternative splice variant of human nucleoside triphosphate diphosphohydrolase 3 (NTPDase3): a possible modulator of nucleotidase activity and purinergic signaling.

Patrick A Crawford1, Keith J Gaddie, Thomas M Smith, Terence L Kirley.   

Abstract

Nucleoside triphosphate diphosphohydrolase 3 (NTPDase3) is a cell surface, membrane-bound enzyme that hydrolyzes extracellular nucleotides, thereby modulating purinergic signaling. An alternatively spliced variant of NTPDase3 was obtained and analyzed. This alternatively spliced variant, termed "NTPDase3beta", is produced through the use of an alternative terminal exon (exon 11) in place of the terminal exon (exon 12) in the full-length NTPDase3, now termed "NTPDase3alpha". This results in an expressed protein lacking the C-terminal cytoplasmic sequence, the C-terminal transmembrane helix, and apyrase conserved region 5. The cDNA encoding this truncated splice variant was detected in a human lung library by PCR. Like the full-length NTPDase3alpha, the alternatively spliced NTPDase3beta was expressed in COS cells after transfection, but only the full-length NTPDase3alpha is enzymatically active and properly trafficked to the plasma membrane. However, when the truncated NTPDase3beta was co-transfected with full-length NTPDase3alpha, there was a significant reduction in the amount of NTPDase3alpha that was properly processed and trafficked to the plasma membrane as active enzyme, indicating that the truncated form interferes with normal biosynthetic processing of the full-length enzyme. This suggests a role for the NTPDase3beta variant in the regulation of NTPDase3 nucleotidase activity, and therefore the control of purinergic signaling, in those cells and tissues expressing both NTPDase3alpha and NTPDase3beta.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17126282      PMCID: PMC1820745          DOI: 10.1016/j.abb.2006.10.013

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  32 in total

1.  Evidence for alternative splicing of ecto-ATPase associated with termination of purinergic transmission.

Authors:  S M Vlajkovic; G D Housley; D Greenwood; P R Thorne
Journal:  Brain Res Mol Brain Res       Date:  1999-11-10

2.  Modified 5-HT3A receptor function by co-expression of alternatively spliced human 5-HT3A receptor isoforms.

Authors:  M Brüss; M Barann; M Hayer-Zillgen; T Eucker; M Göthert; H Bönisch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2000-11       Impact factor: 3.000

3.  Cloning and mapping of a human and mouse gene with homology to ecto-ATPase genes.

Authors:  B P Chadwick; A M Frischauf
Journal:  Mamm Genome       Date:  1997-09       Impact factor: 2.957

4.  Molecular cloning and characterization of expressed human ecto-nucleoside triphosphate diphosphohydrolase 8 (E-NTPDase 8) and its soluble extracellular domain.

Authors:  Aileen F Knowles; Cheryl Li
Journal:  Biochemistry       Date:  2006-06-13       Impact factor: 3.162

5.  Dynamic motions of CD39 transmembrane domains regulate and are regulated by the enzymatic active site.

Authors:  Alison Grinthal; Guido Guidotti
Journal:  Biochemistry       Date:  2004-11-02       Impact factor: 3.162

6.  Characterization of disulfide bonds in human nucleoside triphosphate diphosphohydrolase 3 (NTPDase3): implications for NTPDase structural modeling.

Authors:  Vasily V Ivanenkov; Jarek Meller; Terence L Kirley
Journal:  Biochemistry       Date:  2005-06-28       Impact factor: 3.162

7.  Bacterial expression, folding, purification and characterization of soluble NTPDase5 (CD39L4) ecto-nucleotidase.

Authors:  Deirdre M Murphy-Piedmonte; Patrick A Crawford; Terence L Kirley
Journal:  Biochim Biophys Acta       Date:  2005-01-11

8.  Requirement of Cys399 for processing of the human ecto-ATPase (NTPDase2) and its implications for determination of the activities of splice variants of the enzyme.

Authors:  Jesús Mateo; Silvia Kreda; Christopher E Henry; T Kendall Harden; José L Boyer
Journal:  J Biol Chem       Date:  2003-07-29       Impact factor: 5.157

9.  C-terminal splicing of NTPDase2 provides distinctive catalytic properties, cellular distribution and enzyme regulation.

Authors:  Carol J H Wang; Srdjan M Vlajkovic; Gary D Housley; Norbert Braun; Herbert Zimmermann; Simon C Robson; Jean Sévigny; Christian Soeller; Peter R Thorne
Journal:  Biochem J       Date:  2005-02-01       Impact factor: 3.857

10.  Bacterial expression, characterization, and disulfide bond determination of soluble human NTPDase6 (CD39L2) nucleotidase: implications for structure and function.

Authors:  Vasily V Ivanenkov; Deirdre M Murphy-Piedmonte; Terence L Kirley
Journal:  Biochemistry       Date:  2003-10-14       Impact factor: 3.162

View more
  7 in total

Review 1.  Function of alternative splicing.

Authors:  Olga Kelemen; Paolo Convertini; Zhaiyi Zhang; Yuan Wen; Manli Shen; Marina Falaleeva; Stefan Stamm
Journal:  Gene       Date:  2012-08-15       Impact factor: 3.688

2.  The GDA1_CD39 superfamily: NTPDases with diverse functions.

Authors:  Aileen F Knowles
Journal:  Purinergic Signal       Date:  2011-01-21       Impact factor: 3.765

Review 3.  Cellular function and molecular structure of ecto-nucleotidases.

Authors:  Herbert Zimmermann; Matthias Zebisch; Norbert Sträter
Journal:  Purinergic Signal       Date:  2012-05-04       Impact factor: 3.765

4.  Trafficking and intracellular ATPase activity of human ecto-nucleotidase NTPDase3 and the effect of ER-targeted NTPDase3 on protein folding.

Authors:  Vasily V Ivanenkov; Jean Sévigny; Terence L Kirley
Journal:  Biochemistry       Date:  2008-08-12       Impact factor: 3.162

5.  Characterization of a monoclonal antibody as the first specific inhibitor of human NTP diphosphohydrolase-3 : partial characterization of the inhibitory epitope and potential applications.

Authors:  Mercedes N Munkonda; Julie Pelletier; Vasily V Ivanenkov; Michel Fausther; Alain Tremblay; Beat Künzli; Terence L Kirley; Jean Sévigny
Journal:  FEBS J       Date:  2009-01       Impact factor: 5.542

6.  ENTPD5: identification of splicing variants and their impact on cancer survival.

Authors:  Rafael Paschoal de Campos; Marcia Rosângela Wink; Guido Lenz
Journal:  Purinergic Signal       Date:  2021-06-02       Impact factor: 3.765

7.  The ENTPD5/mt-PCPH oncoprotein is a catalytically inactive member of the ectonucleoside triphosphate diphosphohydrolase family.

Authors:  Caitlin M MacCarthy; Vicente Notario
Journal:  Int J Oncol       Date:  2013-08-06       Impact factor: 5.650

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.